Formycon Strengthens Biosimilars Portfolio With Athos Assets
Deal Will Be Paid For With A Consideration Worth Approximately €650m
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.
You may also be interested in...
Ahead of entering the planned commercialization stage for its first biosimilar product, German biotech Formycon has revealed a series of major announcements, including that it has beefed up its pipeline with an additional two new assets. Meanwhile, it expects to soon find a commercialization partner for its proposed Stelara biosimilar.
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.